U.S., Jan. 14 -- ClinicalTrials.gov registry received information related to the study (NCT07337850) titled 'Prospective Evaluation of 68Ga-FAPI PET in Biliary Cancers' on Jan. 01.
Brief Summary: The goal of this prospective observational study is to evaluate whether Gallium-68 Fibroblast Activation Protein Inhibitor (FAPI) PET/CT can improve detection, staging, and recurrence assessment in adult patients (>=18 years) with suspected or confirmed biliary tract cancers, including gallbladder cancer, cholangiocarcinoma, and post-treatment suspected recurrence.
The main question(s) this study aims to answer are:
Can FAPI PET/CT provide greater sensitivity, specificity and diagnostic accuracy for primary tumors, nodal disease, and metastatic ...